Earnings Feed
Start Free
Home/Filings/4/0001209191-17-061542
4//SEC Filing

NEWMAN MARY 4

Accession 0001209191-17-061542

CIK 0001628738other
View on SEC.govCompany Profile

Filed

Nov 16, 7:00 PM ET

Accepted

Nov 17, 5:06 PM ET

Size

15.3 KB

Accession

0001209191-17-061542

Insider Transaction Report

Form 4
Period: 2017-11-16
Audentes Therapeutics, Inc.BOLD
NEWMAN MARY
SVP, Regulatory Affairs
Transactions
  • Sale

    Common Stock

    2017-11-16$26.49/sh−5,740$152,033→ 0 total
  • Exercise/Conversion

    Common Stock

    2017-11-16$2.19/sh+5,740$12,571→ 5,740 total
  • Exercise/Conversion

    Common Stock

    2017-11-16$2.19/sh+4,260$9,329→ 4,260 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2017-11-16−10,000→ 33,817 total
    Exercise: $2.19Exp: 2025-02-04→ Common Stock (10,000 underlying)
  • Sale

    Common Stock

    2017-11-16$27.31/sh−4,260$116,342→ 0 total
  • Award

    Stock Option (right to buy)

    2017-11-16+50,000→ 50,000 total
    Exercise: $27.39Exp: 2021-11-16→ Common Stock (50,000 underlying)
Footnotes (5)
  • [F1]This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
  • [F2]Represents the weighted average sale price. The lowest price at which shares were sold was $25.96 and the highest price at which shares were sold was $26.90. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
  • [F3]Represents the weighted average sale price. The lowest price at which shares were sold was $26.97 and the highest price at which shares were sold was $27.51.
  • [F4]The option vested as to 25% of the total shares on October 1, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on October 1, 2018, subject to the reporting person's provision of service to the issuer on each vesting date.
  • [F5]The option vests as to 2.0833% of the total shares monthly, beginning December 16, 2017, with 100% of the total shares vested and exercisable on November 16, 2021, subject to the reporting person's provision of service to the issuer on each vesting date.

Documents

1 file

Issuer

Audentes Therapeutics, Inc.

CIK 0001628738

→
Entity typeother

Related Parties

1
  • filerCIK 0001679132

Filing Metadata

Form type
4
Filed
Nov 16, 7:00 PM ET
Accepted
Nov 17, 5:06 PM ET
Size
15.3 KB
View on SEC.gov